



Zai Lab Limited Announces Presentations at November Conferences

November 7, 2018

SHANGHAI, China, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that members of the senior management team will be presenting at four upcoming events in November. Details of the presentations are as follows:

- **BioCentury-BayHelix China Healthcare Summit 2018**

Presentation: Tuesday, November 13, 2018 at 9:00am CT

Presenter: Tao Fu, President & COO

Location: Jing An Shangri-La Hotel, Shanghai

- **Zai Lab / Novocure Investor and Media Event**

Time: Wednesday, November 14, 2018 at 2:30pm CT (1:30am EST)

Presenters: Bill Doyle, Novocure Executive Chairman, Dr. Samantha Du, Zai Lab Founder and CEO, Tao Fu, Zai Lab President & COO

Location: Jing An Shangri-La Hotel, Shanghai

- **Jefferies London Healthcare Conference**

Presentation: Wednesday, November 14, 2018 at 4:00pm GMT (11:00 pm EST)

Presenter: Billy Cho, CFO

Location: The Waldorf Hilton, London

- **Goldman Sachs Asia Pacific Healthcare Forum 2018**

Presentation: Tuesday, November 27, 2018 at 4:15pm CT

Presenter: Billy Cho, CFO

Location: JW Marriott, Hong Kong

Individuals may access webcasts of the Zai Lab / Novocure Investor and Media Event and Jefferies London Conference presentations on the Zai Lab website at www.zailaboratory.com under "Events & Presentations" in the "Investors" section. The webcast will be available on this site for 90 days following the live event.

About Zai Lab

Zai Lab (NASDAQ: ZLAB) is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. The Company's experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China's pharmaceutical market and global unmet medical needs. Zai Lab's vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners' and its own products in order to impact human health worldwide.

Contact:

Zai Lab

Billy Cho

+86 137 6151 2501

billy.cho@zailaboratory.com

Media: Nancie Steinberg / Robert Flamm

Burns McClellan, on behalf of Zai Lab

212-213-0006

nsteinberg@burnsmc.com / rflamm@burnsmc.com

Investors: Jill Steier

Burns McClellan, on behalf of Zai Lab

212-213-0006

jsteier@burnsmc.com



Zai Lab Limited